S

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

mRNA Process Development Co-op

Bioprocess & BiomanufacturingPosted on Nov 13
InternshipBoston, MA, USA$25 - $28 /hrIn-person

About the Job

Requirements

  • Currently pursuing a Bachelor of Science or Master of Science in Biochemistry, Chemical Engineering, Molecular Biology, Bioengineering, Molecular Medicine, Genetics, or a related field.
  • Ability to follow standard operating procedures, make careful observations, and maintain clear and complete records of laboratory work.
  • Ability to present scientific context, experimental setup, data interpretation, and conclusions to a diverse audience.

Responsibilities

  • Execute experiments advancing mRNA manufacturing and process optimization platforms.
  • Produce in vitro transcription-synthesized mRNA.
  • Support screening, optimization, and scale-up for enzymatic reactions, chromatographic separations, and filtration processes, including ultrafiltration, diafiltration, and sterile filtration.
  • Perform analytical assays and characterization studies to evaluate mRNA quality and process performance.
  • Analyze experimental data and contribute to technical presentations, reports, and team discussions.
  • Maintain accurate and detailed experimental records in electronic laboratory notebooks.
  • Support the group's development activities in a fast-paced, collaborative environment.

Desired Qualifications

  • Experience in the biotechnology space is a plus.
  • Experience with nucleic acid workflows, chromatography, filtration processes, or biological analytical techniques is preferred but not required.

About the Company

Strand Therapeutics

Develops programmable, long-acting mRNA therapeutics

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that aim to treat cancer and other life-threatening diseases. The product works by delivering mRNA engineered with logic-based circuits that sense disease-specific cell signals and activate only in diseased cells, increasing the therapeutic window and reducing harm to healthy cells. This enables multi-functional treatments with targeted action rather than non-specific delivery. The company differentiates itself by its programmable mRNA platform that combines gene-encoded logic with disease targeting to achieve cell-type–restricted activity, potentially allowing for safer and more precise therapies compared with conventional mRNA approaches. Strand Therapeutics pursues collaboration and partnerships to expand its programs and generate revenue through development and commercialization of its proprietary mRNA therapeutics with healthcare providers and institutions.

Company size
51-200
Company stage
Series B
Total funding
$256M
Headquarters
Boston, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Strand Therapeutics

See more jobs